The rationale was that low BMD may be due to CKD-MBD (e.g., high PTH) and that lowering PTH is a safer and more appropriate therapy than an antiresorptive (Kidney Disease: Improving Global Outcomes KDIGOCKD–MBD Work Group, 2009). The gene discussed is PTH; the disease is Marchiafava-Bignami disease.